Regeneron Buys Partner Decibel Therapeutics for Up to US$213 M
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 9 (Table of Contents)
Published: 7 Sep-2023
DOI: 10.3833/pdr.v2023.i9.2802 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Expanding its presence in gene therapies, Regeneron has agreed to acquire Decibel Therapeutics for a total equity value of approximately US$109 M at closing, which could rise to approximately US$213 M if contingent value right (CVR) milestones are achieved...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS